Dr. Louca’s research integrates metabolomic, metagenomic, and other multi-omic datasets to elucidate biomarkers, molecular pathways, and host–microbiome interactions relevant to human health and therapeutic response. His work is directed towards identifying and validating candidate targets for intervention, spanning lifestyle modification, pharmacological treatment, and phage-based therapies. Prior to his current appointment, Dr. Louca contributed to the COLO-COHORT study at Newcastle University, one of the largest investigations of gut microbiome–colorectal neoplasia associations.

He is actively engaged in international research consortia, editorial roles, and collaborative initiatives, and has established a strong record of interdisciplinary research leadership aimed at advancing precision medicine and informing public health strategies. He obtained his PhD in Bioinformatics from King’s College London, where he investigated the interplay between the gut microbiome, metabolomics, diet, and hypertension.

His academic training also includes an MSc in Nutrition & Genetics from St. Mary’s University, London, and a BSc in Human Nutrition from Northumbria University. He has authored over 35 peer-reviewed publications, including 17 as first author, and his contributions have been widely cited in the fields of molecular epidemiology, metabolomics, and gut microbiome research.